This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by FitzGerald, G. A. Search for Related Content PubMed Articles by FitzGerald, G. A.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:s51.)
© 2008 American Heart Association, Inc.

Translational Therapeutics at the Platelet Vascular Interface: A CME-Certified Activity

Summary

Garret A. FitzGerald

From the Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia.

Correspondence to G.A. FitzGerald, 153 Johnson Pavilion, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. E-mail garret@spirit.gcrc.upenn.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

This article is part of a multi-part CME-certified activity titled Translational Therapeutics at the Platelet Vascular Interface. In order to achieve all of the activity’s learning objectives, please read all of the components of the activity listed in the Table of Contents and follow the "Instructions for Participation and Obtaining CME Credit" outlined prior to the Introduction.

This meeting illustrates the power of an integrated translational approach to interrogation of the platelet-vascular interface. Increasingly, the technologies and investigations of drug response in cells, model systems, and humans, described by distinct investigators at this meeting, will be integrated by single research groups. We are only beginning to understand that manipulations of a single signaling pathway in a cell may perturb a complex and interdependent system of informational processing. Already, such biological systems paradigms are being exploited in the process of drug discovery. Perhaps it is time for a public-private partnership to accelerate the population of such physiological networks and improve our understanding of how they are disrupted in disease. Presently, such efforts are pursued in relative isolation within companies and academic groupings. However, an expansion of the "precompetitive space" to include the elaboration of networks, leaving the selection of "hubs" and the attendant targeted chemistry protected as intellectual property, would set the stage for the era of systems physiology and pharmacology. Such an informational substrate would build on the achievements of prior public-private genomics and proteomics consortia and contribute ultimately to the personalization or stratification of medicine.

Drug therapy at . . . [Full Text of this Article]